Segment Information

6 Months Ended

Mar. 31, 2022

Segment Reporting [Abstract]

Segment Information

12. Segment Information

Segment revenue, operating (loss) income, and depreciation and amortization were as follows:

	Three Months Ended						Six Months Ended
	March 31,						March 31,
(In thousands)	2022			2021			2022			2021
Revenue:
Medical Device	$	18,453		$	27,907		$	35,361		$	44,103
In Vitro Diagnostics		7,653			7,088			13,748			13,189
Total revenue	$	26,106		$	34,995		$	49,109		$	57,292
Operating (loss) income:
Medical Device	$	(5,612	)	$	8,564		$	(9,404	)	$	7,971
In Vitro Diagnostics		3,720			3,809			6,875			7,029
Total segment operating (loss) income		(1,892	)		12,373			(2,529	)		15,000
Corporate		(3,008	)		(2,890	)		(5,812	)		(5,424	)
Total operating (loss) income	$	(4,900	)	$	9,483		$	(8,341	)	$	9,576
Depreciation and amortization:
Medical Device	$	2,133		$	1,721		$	4,327		$	3,373
In Vitro Diagnostics		86			88			172			193
Corporate		101			97			197			200
Total depreciation and amortization	$	2,320		$	1,906		$	4,696		$	3,766

The Corporate category includes expenses that are not fully allocated to the Medical Device and In Vitro Diagnostics segments. These Corporate costs are related to administrative corporate functions, such as executive management, corporate accounting, information technology, legal, human resources and Board of Directors. Corporate may also include expenses, such as acquisition-related costs and litigation, which are not specific to a segment and thus not allocated to the reportable segments.

Asset information by segment is not presented because the Company does not provide its chief operating decision maker assets by segment, as the data is not readily available.